Onyx ONE

#TCT2019

AMERICAN COLLEGE of CARDIOLOGY

Trial Description: Patients at high bleeding risk undergoing PCI were randomized in a 1:1 fashion to either Resolute Onyx DES or BioFreedom drug-coated stent (DCS) with DAPT for 1 month. They were followed for 1 year.



RESULTS

- Primary safety endpoint, cardiac death/MI/stent thrombosis for Resolute vs. BioFreedom: 17.1% vs. 16.9% (p for noninferiority = 0.011, p for superiority = 0.84)
- BARC 2-5 bleeding: 15.1% vs. 13.7% (p = 0.4)

CONCLUSIONS

- Resolute Onyx (durable polymer DES) implantation is noninferior to BioFreedom (polymer-free DCS), both with 1-month DAPT among patients undergoing PCI and with high bleeding risk
- Ischemic and bleeding rates were very high in both arms, which may be a reflection of the high-risk population studied
- DAPT duration post-DES is an evolving field

Presented by Dr. Stephan Windecker at TCT 2019